BiotechTube

Plixorafenib + Cobicistat 150 MG [Tybost]

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

BRAF V600E Mutation

Conditions

BRAF V600E Mutation

Trial Timeline

Apr 7, 2025 → Jun 30, 2027

NCT ID
NCT06610682

About Plixorafenib + Cobicistat 150 MG [Tybost]

Plixorafenib + Cobicistat 150 MG [Tybost] is a phase 1 stage product being developed by Brain Biotech for BRAF V600E Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06610682. Target conditions include BRAF V600E Mutation.

What happened to similar drugs?

0 of 2 similar drugs in BRAF V600E Mutation were approved

Approved (0) Terminated (1) Active (1)
🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
❌Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06610682Phase 1Recruiting

Competing Products

13 competing products in BRAF V600E Mutation

See all competitors
ProductCompanyStageHype Score
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
TMZ + E7016EisaiPhase 2
27
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
40
encorafenib + Binimetinib + CetuximabOno PharmaceuticalPhase 2
35
Encorafenib + Cetuximab + FOLFIRIMerckPhase 2
35
Tafinlar/MekinistNovartisPre-clinical
33
BKM120 Combined with Vemurafenib (PLX4032)NovartisPhase 1/2
32
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + TislelizumabNovartisPhase 1
21
Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3
32
LGX818 + MEK162 + LEE011PfizerPhase 1/2
32
MEK162PfizerPhase 2
35
Encorafenib + Binimetinib + cemiplimab+fianlimabRegeneron PharmaceuticalsPhase 2
42
Dabrafenib + Trametinib + HydroxychloroquineBrain BiotechPhase 1/2
26